CHICAGO (MedPage Today) -- Patients with newly diagnosed glioblastoma lived no longer with the addition of bevacizumab to chemoradiation than they did without it, results of a large multicenter trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment